Raymond James Upgrades Regeneron Pharmaceuticals to Outperform, Announces $950 Price Target
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Dane Leone has upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from Market Perform to Outperform and set a price target of $950.
November 03, 2023 | 9:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals has been upgraded to Outperform by Raymond James with a price target of $950.
The upgrade from Raymond James is a positive signal for Regeneron Pharmaceuticals. The new rating of Outperform suggests that the analyst believes the company will outperform the market, which could lead to an increase in the stock price. The price target of $950 also indicates a significant upside potential from the current price level.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100